

## FK506 (Tacrolimus) Increases Halothane-induced $Ca^{2+}$ Release from Skeletal Muscle Sarcoplasmic Reticulum

Eduardo N. Chini, M.D., Ph.D.,\* Henry Walker, B.S.†

**Background:** FK506 binding protein is closely associated with the sarcoplasmic reticulum ryanodine receptor-channel and can modulate its function. The ryanodine receptor is stabilized by its association with FK506 binding protein. The immunosuppressant drugs FK506 (tacrolimus) and rapamycin can promote dissociation of FK506 binding protein from the ryanodine receptor 1 and by this mechanism increase sensitivity of ryanodine receptor 1 to agonists such as caffeine. Furthermore, it was shown recently that treatment of normal human skeletal muscle with FK506 and rapamycin increased halothane-induced contracture. The authors investigated the effect of the immunosuppressants FK506 and rapamycin on halothane-induced  $Ca^{2+}$  release in skeletal muscle sarcoplasmic reticulum vesicles.

**Methods:** Skeletal muscle terminal cisterns were isolated from New Zealand White rabbits.  $Ca^{2+}$  uptake and release was monitored in skeletal muscle sarcoplasmic reticulum vesicles using the fluo-3 fluorescent technique. Western Blot analysis of FK506 binding protein was performed using standard protocol.

**Results:** The authors observed that treatment of skeletal muscle sarcoplasmic reticulum vesicles with FK506 and rapamycin enhances halothane-induced  $Ca^{2+}$  release by about five times. Furthermore, the  $Ca^{2+}$  release induced by halothane in the presence of FK506 was inhibited by several antagonists of the ryanodine receptor, such as ruthenium red, spermine, and  $Mg^{2+}$ .

**Conclusion:** Dissociation of FK506 binding protein from its binding site in skeletal muscle sarcoplasmic reticulum vesicles can modulate halothane-induced  $Ca^{2+}$  release through the ryanodine receptor. Data are discussed in relation to the role of the FK506 binding protein in modulating the effect of halothane on the ryanodine receptor and the development of malignant hyperthermia phenotype. (Key words: Immunosuppression; malignant hypothermia, ryanodine channel.)

\* Anesthesiology Resident.

† Research Technologist.

Received from the Departments of Physiology, Biophysics, and Anesthesiology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota. Submitted for publication June 16, 1999. Accepted for publication December 9, 1999. Supported in part by an American Heart Association (Minnesota affiliate, Minneapolis, Minnesota) grant-in-aid (Dr. Chini).

Address reprint requests to Dr. Chini: 917 Guggenheim Building, Mayo Clinic, Rochester, Minnesota 55905. Address electronic mail to: chini.eduardo@mayo.edu

SKELETAL muscle contraction is triggered by  $Ca^{2+}$  release from the sarcoplasmic reticulum<sup>1</sup> and is mediated by the ryanodine receptor (RyR) channel. The majority of skeletal muscle RyRs consists of RyR type 1 (RyR1).<sup>1</sup> The receptor has been cloned, and its molecular weight as deduced from the primary amino acid sequence, is 565,000 d<sup>1,2</sup>; native RyR1 is a homotetramer.<sup>1,2</sup> Recently, the function of RyR1 was shown to be regulated by several accessory proteins.<sup>1-4</sup> Malignant hyperthermia (MH) is a pharmacogenetic skeletal muscle disease that is characterized by sustained muscle contraction and abrupt increase in body temperature during general anesthesia.<sup>5-7</sup> Dysfunction of the skeletal muscle  $Ca^{2+}$  release system in response to volatile anesthetics, such as halothane, is a key point in the pathogenesis of MH.<sup>5-7</sup> Linkage of the MH phenotype with the *RyR1* gene has been described<sup>5,6</sup>; however, mutations in *RyR1* account for approximately 50% of the human cases of MH.<sup>6</sup> It is possible that modulatory proteins, such as FK506 binding protein (FKBP), that regulate the function of RyR also may be involved in the pathogenesis of a number of genetic variants of MH.

FK506 binding protein 12 is closely associated with the sarcoplasmic reticulum RyR<sup>2-4</sup> and can modulate its function.<sup>2-4</sup> If FKBP is bound to the RyR, its  $Ca^{2+}$  channel is stabilized in the closed position and is less likely to permit leakage of  $Ca^{2+}$  from sarcoplasmic reticulum.<sup>2-4</sup> The immunosuppressant drugs FK506 (tacrolimus) and rapamycin can promote dissociation of FKBP from the RyR<sup>2-4</sup> and, by this mechanism, can increase sensitivity of the RyR1 to agonists such as caffeine.<sup>2-4</sup> Furthermore, it was shown recently that treatment of normal human skeletal muscle with FK506 and rapamycin increases halothane-induced contracture.<sup>8</sup> In fact, FK506- and rapamycin-treated human skeletal muscle behaves in a manner similar to MH-susceptible skeletal muscle.<sup>8</sup> No direct evidence of regulation of halothane-induced  $Ca^{2+}$  release by FK506 or rapamycin, however, has been presented to date. In view of these findings, we investigated

the effect of FK506 and rapamycin on halothane-induced  $\text{Ca}^{2+}$  release in skeletal muscle sarcoplasmic reticulum. We found that dissociation of FKBP from its binding site at the sarcoplasmic reticulum vesicles, induced by FK506 and rapamycin, can increase halothane-triggered  $\text{Ca}^{2+}$  release mediated through the RyR.

## Materials and Methods

### *Isolation of Sarcoplasmic Reticulum Vesicles*

These experiments were performed in accordance with the National Institutes of Health Guidelines on the Use of Laboratory Animals and were approved by the Mayo Clinic Institutional Animal Care Committee. Sarcoplasmic reticulum terminal cisternae vesicles (SRVs) were isolated from New Zealand White rabbit skeletal muscle, as described previously.<sup>9</sup> Predominant white muscle of the hind leg was separated from muscle that was pink and from connective tissue. Dissection was performed on a glass tray placed on packed ice. The muscle was ground and a 50-g portion was homogenized in 250 ml homogenizing media (0.3 [mcap]m sucrose, 5 mM imidazole-HCl [pH 7.4]), using a blender at maximum speed for 1 min. The SRVs were isolated by differential centrifugation and sucrose gradient, as described by Saito *et al.*<sup>9</sup> After isolation, the SRVs were suspended in homogenization medium, quick-frozen, and stored at  $-70^{\circ}\text{C}$ . The  $\text{Ca}^{2+}$  loading and release properties of the SRV were not found to be compromised by storage at  $-70^{\circ}\text{C}$ . After  $\text{Ca}^{2+}$  loading, the baseline  $\text{Ca}^{2+}$  levels were approximately  $27.8 \pm 6$  mmol in three different preparations and were consistent from day to day.

### *$\text{Ca}^{2+}$ Release Assay*

Frozen sarcoplasmic reticulum was thawed in a  $37^{\circ}\text{C}$  water bath and diluted to 1.0 mg/ml in an intracellular media solution that contained 250 mM *N*-methyl glucamine, 250 mM potassium gluconate, 20 mM HEPES buffer (pH 7.2), 1 mM  $\text{MgCl}_2$ , and 20 mM potassium phosphate. For  $\text{Ca}^{2+}$ -release experiments, sarcoplasmic reticulum vesicles were loaded actively with  $\text{Ca}^{2+}$  with an adenosine triphosphate-regenerative system consisting of 2 U/ml creatine kinase, 4 mM phosphocreatine, and 1 mM adenosine triphosphate.  $\text{Ca}^{2+}$  uptake and release were monitored as described previously using  $3\text{-}\mu\text{M}$  fluo-3.<sup>10</sup> Fluo-3 fluorescence was monitored at 490-nm excitation and 535-nm emission in a  $250\text{-}\mu\text{l}$  cuvette at  $37^{\circ}\text{C}$  with a circulating water bath and continuously mixed with a magnetic


stirring bar using a spectrofluorometer (F-2000; Hitachi, San Jose, CA).<sup>10</sup> We observed no changes in the properties of fluo-3 (emission, excitation, or response to exogenous  $\text{Ca}^{2+}$ ) in the presence of all tested compounds. In addition, no significant photobleaching was observed. The addition of stock solutions of various substances did not exceed 1% of homogenate volume in the cuvette. Furthermore, in control experiments, FK506, rapamycin, or halothane treatments did not have any significant effect on the rate of  $\text{Ca}^{2+}$  uptake of SRVs measured in the presence of ruthenium red. In these control experiments, ruthenium red was used to promote inhibition of the RyRs and prevent interference of halothane, FK506, and rapamycin on the  $\text{Ca}^{2+}$  channel leaking pathway.

### *Western Blot Analysis of FK506 Binding Protein*

Soluble FKBP supernatant was diluted to 1 mg/ml in extraction buffer that contained 0.3 M sucrose and 5 mM imidazole-HCl at a pH of 7.4. Samples were diluted at concentration of 1:2 with sample buffer, and 20  $\mu\text{g}$  was resolved in a 15% tris-HCl gel (Bio-Rad 161-1157) in tris-glycine-SDS (Bio-Rad 161-0732, Hercules, CA). Protein was transferred to nitrocellulose membrane (Bio-Rad 162-0145) in a minitransblot apparatus at 200 mA for 1 h in 25 mM tris, 192 mM glycine, and 20% (vol/vol) methanol (pH 8.3) surrounded by ice. The blotted membrane was blocked overnight at  $4^{\circ}\text{C}$  in tris buffer solution with Tween, containing 0.1% Tween 80 and 5% (wt/vol) powdered milk, and probed 1 h with anti-FKBP 12 goat antiserum (Santa-Cruz Biotechnology, Santa Cruz, CA) diluted at a concentration of 1:200 in blocking buffer. After repetitive washes with tris-buffer solution with Tween, the membrane was probed with secondary antibody (antigoat immunoglobulin G-horseradish peroxidase) (Piscataway, NJ) for 45 min and developed using Amersham ECL detection reagents. Films were analyzed on a Bio-Rad Fluor S Multi imager set to use radiographic film.

### *Materials*

Fluo-3 was purchased from Molecular Probes (Eugene, OR), FK506 from Biomol (Plymouth Meeting, PA). All other reagents, the most pure available, were supplied by Sigma (St. Louis, MO). The reported experiments were repeated at least three to six times in three different preparations.


FK506 POTENTIATES HALOTHANE-INDUCED  $\text{Ca}^{2+}$  RELEASE

**Fig. 1.** Dissociation of FK506 binding protein from sarcoplasmic reticulum terminal cisternae vesicles (SRVs). One milligram SRVs per milliliter was incubated at 37°C for 40 min without or with 25  $\mu\text{M}$  FK506. After incubation, SRVs were centrifuged for 30 min at 50,000g in a Beckman 50.4 Ti rotor (Palo Alto, CA) at 4°C, and the supernatant was collected. The figure shows the SDS-PAGE and western blot analysis for FK506 binding protein 12 in the collected supernatant of control (lanes 1 and 2) and FK506-treated (lanes 3 and 4) SRVs.

## Results

### *Effect of FK506 on Caffeine- and $\text{Ca}^{2+}$ -induced $\text{Ca}^{2+}$ Release*


Dissociation of FKBP from SRVs by FK506 was confirmed by western blot analysis using an antibody to FKBP. Figure 1 clearly indicates that treatment of SRVs with FK506 results in the appearance of FKBP in the supernatant fraction, indicating that, in our preparation, treatment with FK506 promotes dissociation of FKBP from SRVs. We also confirmed previous results that indicated FKBP modulates agonist-induced  $\text{Ca}^{2+}$  release through the RyR.<sup>2-4</sup> As previously described, treatment of SRVs with FK506 increases the rate of  $\text{Ca}^{2+}$  release induced by caffeine.<sup>2-4</sup> We observed that pretreatment of SRVs with 25  $\mu\text{M}$  FK506 increased the  $\text{Ca}^{2+}$  release induced by 1 mM caffeine approximately fivefold (from  $7.8 \pm 2.7$  to  $35.5 \pm 5.3$  nmol  $\text{Ca}^{2+}$  per 2 min). Furthermore, we observed that SRVs treated with FK506 were more sensitive to  $\text{Ca}^{2+}$  release induced by  $\text{Ca}^{2+}$  itself. In SRVs not treated with FK506, serial additions of  $\text{Ca}^{2+}$  by itself were not sufficient to cause  $\text{Ca}^{2+}$  release. In approximately 40% of SRVs treated with FK506, however, serial additions of  $\text{Ca}^{2+}$  were able to promote  $\text{Ca}^{2+}$  release (fig. 2).



**Fig. 2.** Effect of FK506 on  $\text{Ca}^{2+}$  release induced by  $\text{Ca}^{2+}$ . One milligram sarcoplasmic reticulum terminal cisternae vesicles (SRVs) per milliliter was loaded actively with  $\text{Ca}^{2+}$  by addition of 1 mM adenosine triphosphate in the presence of an adenosine triphosphate-regenerative system. Before  $\text{Ca}^{2+}$  loading and challenging with sequential additions of  $\text{Ca}^{2+}$ , SRVs were incubated at 37°C for 40 min in the absence (A) or presence (B) of 25  $\mu\text{M}$  FK506. After active  $\text{Ca}^{2+}$  uptake, the extravesicular concentration of  $\text{Ca}^{2+}$  was essentially the same for control and FK506-treated SRVs. The lower arrows indicate single additions of 10 nmol  $\text{Ca}^{2+}$ . The  $\text{Ca}^{2+}$  release induced by seven sequential additions of 10 nmol  $\text{Ca}^{2+}$  was observed in approximately 5 of 12 (40%) SRVs treated with FK506. In contrast, up to eight sequential additions of 10 nmol  $\text{Ca}^{2+}$  produced no  $\text{Ca}^{2+}$ -induced release of  $\text{Ca}^{2+}$  in control SRVs (0 of 14).


### *Effect of FK506 on Halothane-induced $\text{Ca}^{2+}$ Release*

We also tested the effect of FK506 on  $\text{Ca}^{2+}$  release induced by halothane. As shown in figure 3, treatment of SRVs with 0.4% (vol/vol) halothane produced a slow rate of  $\text{Ca}^{2+}$  release, which is in agreement with previously published observations.<sup>7</sup> In SRVs pretreated with FK506, the rate of  $\text{Ca}^{2+}$  release induced by halothane was increased approximately fivefold (fig. 3B). Furthermore, the binding of halothane appears to be increased by treatment of SRVs with FK506 (fig. 3). To determine whether  $\text{Ca}^{2+}$  release induced by halothane, in the presence of FK506, was mediated by activation of RyRs, we investigated the effect of several inhibitors of RyRs.<sup>11</sup> As previously described,  $\text{Ca}^{2+}$  release through RyRs can be inhibited by ruthenium red,  $\text{Mg}^{2+}$ , and spermine. As shown in figure 4, halothane-induced  $\text{Ca}^{2+}$  release in SRVs pretreated with FK506 was abolished if the vesicles were treated with the three inhibitors of RyR. These data indicate that the effect of halothane observed here is mediated through activation of RyR. It was reported previously that the immunosuppressant rapamycin, by promoting dissociation of FKBP from its binding site at



**Fig. 3.** Effect of FK506 on halothane-induced  $\text{Ca}^{2+}$  release.  $\text{Ca}^{2+}$  release in 1.0 mg sarcoplasmic reticulum terminal cisternae vesicles/ml was monitored using fluo-3 as a  $\text{Ca}^{2+}$  indicator. (A)  $\text{Ca}^{2+}$  release initiated by addition of 0.4% (vol/vol) halothane. (B) The rate of  $\text{Ca}^{2+}$  release induced by different concentrations of halothane in control vesicles ( $\square$ ) or pretreated with 25  $\mu\text{M}$  FK506 ( $\bullet$ ) as described in figure 2. The data are representative of four independent experiments. The data represent the mean  $\pm$  SD;  $n = 4$  independent experiments.

the SRV, also can potentiate  $\text{Ca}^{2+}$  release induced by caffeine through RyRs.<sup>4</sup> Finally, we observed that rapamycin also was able to increase halothane-induced  $\text{Ca}^{2+}$  release in SRVs from  $7.8 \pm 2.7$  to  $24.7 \pm 5.6$  nmol of  $\text{Ca}^{2+}$  per 2 min. Furthermore, pretreatment of SVRs with 20  $\mu\text{M}$  cyclosporine for 40 min before  $\text{Ca}^{2+}$  loading had no effect on halothane-induced  $\text{Ca}^{2+}$  release.



**Fig. 4.** Effect of inhibitors on halothane-induced  $\text{Ca}^{2+}$  release. Before  $\text{Ca}^{2+}$  loading and release, sarcoplasmic reticulum terminal cisternae vesicles were preincubated with 25  $\mu\text{M}$  FK506, as described in figure 2. Furthermore, before the addition of 0.4% (vol/vol) halothane,  $\text{Ca}^{2+}$ -loaded vesicles were incubated for 1 min alone (control) or with 30  $\mu\text{M}$  ruthenium red. (Inset) Effect of several inhibitors on 0.4% halothane-induced  $\text{Ca}^{2+}$  (taken at 100%) with no further addition (control; C) or incubated for 1 min with 30  $\mu\text{M}$  ruthenium red (RR), 3 mM spermine (Spm); or 10 mM  $\text{MgCl}_2$  (Mg) in  $\text{Ca}^{2+}$ -loading vesicles. The data represent the mean  $\pm$  SD;  $n = 3$  independent experiments.

**Discussion**

Treatment of SRVs with the immunosuppressant FK506 and rapamycin can increase halothane-induced  $\text{Ca}^{2+}$  release. We also observed that SRVs treated with FK506 are more sensitive to  $\text{Ca}^{2+}$ -induced release of  $\text{Ca}^{2+}$ . The results observed here probably are related to dissociation of FKBP from RyRs. As described previously, dissociation of FKBP from RyRs increases sensitivity of RyRs to agonists.<sup>2-4</sup> Also,  $\text{Ca}^{2+}$  release induced by halothane, as observed here, appears to be mediated by RyR because inhibitors of RyR, such as ruthenium red, spermine, and  $\text{Mg}^{2+}$ , were able to block the effect of halothane.

It was shown previously that treatment of normal skeletal muscle with FK506 and rapamycin can produce an MH-like phenotype, as observed in muscle contracture studies.<sup>8</sup> No direct evidence indicating modulation of  $\text{Ca}^{2+}$  release in response to halothane, however, was observed.<sup>8</sup> It is possible that *in vivo* dissociation of FKBP 12 from RyR1 may be an important component in the pathophysiology of MH. As discussed previously, in some instances, the cellular defect responsible for development of MH has not been determined.<sup>5,6,8</sup> Mutations in FKBP or RyR that can modify the interaction between

Downloaded from http://esa2.silverplatter.com/ at the University of California, San Diego on February 26, 2015

these two proteins might result in MH phenotypes. No such mutations, however, have been described to date. Finally, it is possible that by modulating the RyR, not only in skeletal muscle, but also in cardiac and smooth muscle, the clinical use of these immunosuppressants may have an important influence on the anesthetic management of patients.

The authors thank Dr. Claudia C. S. Chini, Ph.D., for critical reading of the manuscript. This work is dedicated to the memory of Dr. Thomas P. Dousa, M.D., Ph.D., who contributed greatly to science and understanding.

## References

1. Coronado R, Morrissette J, Sukhareva M, Vaughan DM: Structure and function of ryanodine receptor. *Am J Physiol* 1994; 266:C1485-504
2. Marks AR: Intracellular calcium-release channels: Regulators of cell life and death. *Am J Physiol* 1997; 272:H597-605
3. Timerman AP, Ogunbumni E, Freud E, Widerrecht G, Marks AR, Fleisher S: The calcium release channel of sarcoplasmic reticulum is modulated by FK-506 binding protein. *J Biol Chem* 1993; 268:22992-9
4. Brillantes AMB, Ondrias K, Scott A, Kobrinsky E, Odriasova E, Moschella MC, Jayaraman T, Landers M, Ehrlich BE, Marks AR: Stabilization of calcium release channel (ryanodine receptor) function by FK-506 binding protein. *Cell* 1994; 77:513-23
5. MacLennan DH: Discordance between phenotype and genotype in malignant hyperthermia. *Curr Opin Neurol* 1995; 8:397-401
6. Levitt RC, Olckers A, Meyers S, Fletcher JE, Rosenberg H, Isaacs H, Meyers DA: Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. *Genomics* 1992; 14:534-47
7. Ogawa Y, Kurebayashi N: The Ca-releasing action of halothane on fragmented sarcoplasmic reticulum. *J Biochem (Tokyo)* 1982; 92:899-905
8. Brooksbank RL, Bedenhorst ME, Issacs H, Savage N: Treatment of normal skeletal muscle with FK506 or rapamycin results in halothane-induced muscle contracture. *ANESTHESIOLOGY* 1998; 89:693-8
9. Saito A, Seiler S, Chu A, Fleischer S: Preparation and morphology of sarcoplasmic reticulum terminal cisternae from rabbit skeletal muscle. *J Cell Biol* 1984; 99:875-85
10. Chini EN, Beers KW, Dousa TP: Nicotinic acid adenine dinucleotide phosphate (NAADP) triggers specific calcium release system in sea urchin eggs. *J Biol Chem* 1995; 270:3216-23
11. Chini EN, Dousa TP: Palmitoyl-CoA potentiates the  $\text{Ca}^{2+}$  release elicited by cyclic ADP-ribose. *Am J Physiol* 1996; 270:C530-7